Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis

Liver Cirrhosis Clinical Trial

Official title:

Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05848414
• Other study ID #: Liver cirrhosis mortality
• Status: Not yet recruiting
• Start date: February 7, 2024
• Est. completion date: June 7, 2024

Study information

• Verified date: January 2024
• Source: Assiut University
• Contact: Esraa H Kotbey, Resident
• Phone: 01065186086
• Email: skotbey1995[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study will be conducted to assess the baseline characteristics and evaluate the 90-day mortality of patients admitted with liver cirrhosis. Also, the study will be done to identify the risk factors of 90-day mortality.

Description:

Liver cirrhosis is the end spectrum of all chronic liver diseases characterized by advanced fibrosis, scarring, and formation of regenerative nodules leading to hepatic architectural distortion. Liver cirrhosis is a major cause of health burden worldwide. According to the Global Burden of Disease study, liver cirrhosis caused 1.2% of global disability-adjusted life years and 2% of all deaths worldwide in 2010, the 14th leading cause of mortality. The progress rate of compensated cirrhosis to decompensated cirrhosis is approximately 58% and once it progresses to decompensated cirrhosis, its mortality rate within 5 years becomes 85% without liver transplantation. Since the progression of cirrhosis is accelerated each time a complication recurs, the management and treatment of the complication are critical in enhancing the quality of life and the life expectancy of patients . Post-discharge outcomes are an integral component of healthcare, as they may aid in determining the success and longevity of treatment and how clinicians approach future cases . This study will focus on the short-term outcomes of patients hospitalized with liver cirrhosis to provide insight into methods for future healthcare interventions.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: June 7, 2024
• Est. primary completion date: June 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• diagnosis of liver cirrhosis, adult (age = 18 years old) and patients willing to give consent during the selected period.

Exclusion Criteria:

• Patients with ages < 18 years or patients that will be lost on follow-up will be excluded from the study.

Related Conditions & MeSH terms

• Fibrosis
• Liver Cirrhosis

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (1)

Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014 May 17;383(9930):1749-61. doi: 10.1016/S0140-6736(14)60121-5. Epub 2014 Jan 28. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	evaluate the 90-day mortality of patients admitted with liver cirrhosis	Mortality	90 days
Secondary	identify the risk factors of 90-day mortalit	Risk factors for mortality	90 days